Cargando…
Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors
Ipilimumab is a monoclonal antibody that enhances the efficacy of the immune system by targeting a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is a protein receptor that downregulates the immune system. Nivolumab is also a humanized monoclonal antibody that targets another protein re...
Autores principales: | Youssef, Alexey, Kasso, Nawara, Torloni, Antonio Sergio, Stanek, Michael, Dragovich, Tomislav, Gimbel, Mark, Mahmoud, Fade |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317083/ https://www.ncbi.nlm.nih.gov/pubmed/30671268 http://dx.doi.org/10.1155/2018/2464619 |
Ejemplares similares
-
Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023) -
REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA DUE TO COVID-19
por: CABRERA, RUBEN, et al.
Publicado: (2021) -
Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011) -
Dengue and Thrombotic Thrombocytopenic Purpura
por: Wiwanitkit, Viroj
Publicado: (2017)